HILS Stock Price, Hillstream BioPharma, . Quote, Chart

Market Summary

USD1816.00-12.00

Market Closed

-0.66%

HILS Stock Price

View Fullscreen

HILS RSI Chart

HILS Valuation

Market Cap

22.4B

Price/Earnings (Trailing)

-2.4K

Price/Sales (Trailing)

146.8K

Price/Free Cashflow

-3.1K

HILS Price/Sales (Trailing)

HILS Profitability

Return on Equity

-102.06%

Return on Assets

-85.13%

Free Cashflow Yield

-0.03%

HILS Fundamentals

HILS Revenue

Revenue (TTM)

152.6K

Rev. Growth (Qtr)

102.92%

HILS Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

-40.04%

Earnings Growth (Qtr)

-35.91%

Breaking Down HILS Revenue

Last 7 days

-4.8%

Last 30 days

-0.8%

Last 90 days

9.8%

Trailing 12 Months

465779.9%

How does HILS drawdown profile look like?

HILS Financial Health

Current Ratio

6.03

HILS Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-24.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	152.6K
2022	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hillstream BioPharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 14, 2022	appajosyula sireesh	gifted	-	-	-75,757	-
Jul 14, 2022	appajosyula sireesh	gifted	-	-	7,576	-
Jun 17, 2022	milby randy	bought	389	0.7799	500	chief executive officer
Jun 06, 2022	milby randy	bought	688	0.688463	1,000	chief executive officer
Jun 01, 2022	milby randy	bought	0.94	0.94	1.00	chief executive officer
May 25, 2022	milby randy	bought	786	0.786	1,000	chief executive officer
May 20, 2022	milby randy	bought	918	0.91825	1,000	chief executive officer
May 19, 2022	milby randy	bought	907	0.90765	1,000	chief executive officer
Apr 18, 2022	milby randy	acquired	24,341	0.101203	240,526	chief executive officer
Jan 14, 2022	milby randy	acquired	884,125	3.2	276,289	chief executive officer

Which funds bought or sold HILS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 26, 2024	Virtu Financial LLC	new	-	53,000	53,000	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-4,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	10,041	10,041	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-11,414	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-5,154	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-7,549	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	new	-	688	688	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-3,813	-	-%
Feb 09, 2024	UBS Group AG	sold off	-100	-8,766	-	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	new	-	3.00	3.00	-%

Are Funds Buying or Selling HILS?

Are funds buying HILS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HILS

No. of Funds

Unveiling Hillstream BioPharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Dec 07, 2023	tang capital partners lp	9.99%	252,549	SC 13G

Recent SEC filings of Hillstream BioPharma, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 22, 2024	DEFA14A	DEFA14A
Mar 22, 2024	ARS	ARS
Mar 21, 2024	DEFA14A	DEFA14A
Mar 21, 2024	DEF 14A	DEF 14A
Mar 11, 2024	PRE 14A	PRE 14A
Mar 11, 2024	8-K	Current Report
Feb 23, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	8-K	Current Report

Peers (Alternatives to Hillstream BioPharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-1.15%	-18.78%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-5.46%	-27.26%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-6.36%	-11.66%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.50%	-30.40%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.4B	-	-18.25%	70.26%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.32%	-19.69%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.79%	-8.36%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.14%	-47.54%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-7.41%	335.24%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.26%	4.12%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Hillstream BioPharma, Inc. News

Latest updates

Hillstream BioPharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Revenue	102.9%	58.00	28.00	34.00	32.00	-
Operating Expenses	37.2%	2,531	1,845	2,365	2,714	1,766
S&GA Expenses	13.4%	1,538	1,357	1,334	1,667	1,083
R&D Expenses	103.4%	993	488	1,031	1,048	683
Interest Expenses	-89.9%	354*	3.00	7.00	6.00	-
Net Income	-35.9%	-2,473	-1,820	-2,336	-2,688	-1,766
Net Income Margin	-Infinity%	-61.06*	-	-	-	-
Free Cashflow	-55.6%	-1,400	-900	-1,535	-3,464	-892

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	245.6%	10,946	3,167	4,599	4,722	6,689	8,018	10,248	12,091	622	-
Current Assets	245.6%	10,946	3,167	4,599	4,722	6,689	8,018	10,248	12,091	622	295
Cash Equivalents	306.7%	10,935	2,689	3,904	3,569	6,511	7,597	9,484	11,122	4.00	192
Liabilities	28.7%	1,815	1,410	1,530	1,521	1,145	902	1,208	1,752	5,307	4,012
Current Liabilities	28.7%	1,815	1,410	1,530	1,521	1,145	902	1,208	1,752	4,534	2,725
Shareholder's Equity	419.7%	9,131	1,757	3,069	3,201	5,544	7,116	9,040	10,339	-4,684	-
Retained Earnings	-11.1%	-24,703	-22,229	-20,409	-18,072	-15,384	-13,617	-11,490	-9,853	-6,911	-4,704
Additional Paid-In Capital	40.9%	33,904	24,055	23,547	21,342	20,998	20,795	20,554	20,191	2,226	986
Shares Outstanding	-33.0%	11,740	17,512	16,814	11,514	-	11,532	11,104	11,364	6,357	6,357
Float	-	-	-	3,900	-	-	-	5,600	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-55.6%	-1,400	-900	-1,500	-3,500	-892	-1,548	-1,373	-2,742	-7.67	-316	-269	-492	-
Share Based Compensation	7.9%	170	158	158	345	202	241	339	19.00	7.00	4.00	554	674	-
Cashflow From Financing	3257.4%	9,662	-306	1,846	523	-193	-338	-249	13,846	-33.06	333	276	323	-

HILS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 3,559,635	$ 2,278,424
General and administrative	5,895,585	4,603,514
Total operating expenses	9,455,220	6,881,938
Loss from operations	(9,455,220)	(6,881,938)
Other income (expense)
Interest expense	(16,505)	(1,591,244)
Interest income	152,631
Total other income (expense), net	136,126	(1,591,244)
Net loss	$ (9,319,094)	$ (8,473,182)
Net loss per share:
Basic	$ (7.14)	$ (18.72)
Diluted	$ (7.14)	$ (18.72)
Weighted average number of common shares outstanding:
Basic	1,305,437	452,686
Diluted	1,305,437	452,686

HILS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 10,935,352	$ 6,510,534
Prepaid expenses and other current assets	11,041	178,094
Total current assets	10,946,393	6,688,628
Total assets	10,946,393	6,688,628
Current liabilities
Accounts payable	908,577	954,505
Accrued expenses	906,469	190,468
Total current liabilities	1,815,046	1,144,973
Total liabilities	1,815,046	1,144,973
Commitments and contingencies (see Note 9)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized,11,743,309 shares and 464,213 shares issued and 11,739,676 shares and 460,580 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	1,175	46
Additional paid-in capital	33,903,663	20,998,006
Accumulated deficit	(24,703,526)	(15,384,432)
Treasury stock, at cost, 3,633 shares held in treasury as of December 31, 2023 and December 31, 2022	(69,965)	(69,965)
Total stockholders’ equity	9,131,347	5,543,655
Total liabilities and stockholders’ equity	$ 10,946,393	$ 6,688,628

About Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

CEO	Mr. Randy D. Milby MBA
WEBSITE	hillstreambio.com
INDUSTRY	Biotechnology
EMPLOYEES	1

Hillstream BioPharma, Inc. Frequently Asked Questions

What is the ticker symbol for Hillstream BioPharma, Inc.? What does HILS stand for in stocks?

HILS is the stock ticker symbol of Hillstream BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hillstream BioPharma, Inc. (HILS)?

As of Thu Feb 29 2024, market cap of Hillstream BioPharma, Inc. is 22.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers. The fair value of Hillstream BioPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hillstream BioPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HILS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hillstream BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether HILS is over valued or under valued. Whether Hillstream BioPharma, Inc. is cheap or expensive depends on the assumptions which impact Hillstream BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HILS.

What is Hillstream BioPharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, HILS's PE ratio (Price to Earnings) is -2403.59 and Price to Sales (PS) ratio is 146.75 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HILS PE ratio will change depending on the future growth rate expectations of investors.